GlassScriptPhysician profile
Oliver M Bennett
NPI 1467429415
$2,700.33
in general payments reported to CMS, 2019-2025
22 companies · $37.34 in 2025
The $37.34 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $414 · 2021: $699 · 2022: $651 · 2023: $561 · 2024: $33.41 · 2025: $37.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $406.04 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $398.63 | 2020-2022 | |
| Lilly USA, LLC | $347.52 | 2019-2024 | Amyvid, Mounjaro |
| Biogen, INC. | $343.17 | 2019-2023 | Vumerity, Tysabri |
| Novo Nordisk INC | $289.93 | 2019-2021 | |
| Abbvie INC. | $127.78 | 2022-2023 | Ubrelvy |
| Vanda Pharmaceuticals INC. | $121.85 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $115.33 | 2023 | Aptiom |
| Argenx US, INC. | $90.19 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $69.23 | 2022 | |
| Global Blood Therapeutics, INC. | $66.03 | 2022 | |
| Ucb, INC. | $61.86 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $41.42 | 2021 | |
| Avanir Pharmaceuticals, INC. | $34.84 | 2019 | |
| Exact Sciences Corporation | $31.47 | 2023-2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $30.57 | 2023 | |
| Alnylam Pharmaceuticals INC. | $28.17 | 2022 | |
| Eisai INC. | $23.98 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.90 | 2025 | Keveyis |
| Acorda Therapeutics, INC | $17.52 | 2023 | Inbrija, Ampyra |
| Livanova USA, INC. | $17.46 | 2022 | |
| Amgen INC. | $15.44 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.